Read Full Story
Enter email for updates from this topic
In December, MesotheliomaHelp.org
reported the U.S. Food and Drug Administration approved Portrazza (necitumumab) for first-line treatment of people with metastatic squamous non-small cell lung cancer. Now, researchers confirm necitumumab is most Beneficial to
Lung Cancer Patients expressing epidermal growth factor receptor (EGFR)
EGFR is a protein found on the surface of some cells to which epidermal growth factor binds, which causes the cells to divide and spread. It is found at abnormally high levels on the surface of many types of cancer cells, including more than 50% of pleural mesothelioma patients
, and approximately 15% of lung cancer in the U.S. Necitumumab blocks the activity of EGFR.